Validation of the Clinical Assessment Scale for Autoimmune Encephalitis in a Severe Autoimmune Encephalitis Cohort

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 17

PMID 39687624

Authors

Yu He

Fangfang Li

Ali Yang

Chen Yu

Yifan Wang

Jing Zhao

Weizhou Zang

Affiliations

Soon will be listed here.

Abstract

Objective: The Clinical Assessment Scale for Autoimmune Encephalitis (CASE) is a novel tool tailored specifically for evaluating the severity of autoimmune encephalitis (AE). However, its application in severe AE patients is limited. This study aimed to evaluate the reliability and validity of the CASE and explore its clinical significance in a severe AE cohort.

Methods: The relevant clinical characteristics, laboratory data, and prognosis of patients diagnosed with severe AE between April 2017 and April 2023 were collected. The CASE and modified Rankin scale (mRS) were performed at admission, discharge, and 1-year follow-up, respectively. The reliability of CASE was validated by calculating the Cronbach's alpha value. The validity was evaluated by calculating the Spearman's rank correlation with the corresponding mRS. Univariate and multivariate logistic regression were utilized to identify risk factors for poor prognosis.

Results: A total of 140 patients were recruited for the study. The CASE scale presented great internal consistency, with Cronbach's α value of 0.768 for the total score. The Spearman's rank correlation analysis revealed strong criterion validity between CASE and mRS, with coefficients of 0.68, 0.92, and 0.95 at admission, discharge, and 1-year follow-up, respectively (all < 0.001). ROC analysis identified CASE score at admission served as a promising predictive marker for clinical response to treatment, with an AUC of 0.67 (95% CI: 0.57-0.77, = 0.003). The optimal cut-off point was 22.5. At 1-year follow-up, 72/140 (51.4%) patients achieved good functional status (mRS, 0-2). Multivariate logistic regression confirmed that higher CASE scores on admission and older age at onset were associated with poor short-term as well as 1-year prognosis, respectively. In addition, no clinical response to treatment (OR = 40.499; 95% CI: 7.077-231.746, < 0.001) and longer duration of hospitalization (OR = 1.071; 95% CI: 1.017-1.128, = 0.010) were associated with poor function states at 1-year follow-up.

Conclusion: The CASE has proven suitable for evaluating disease severity and prognosis in severe AE patients. Besides, CASE score, age at disease onset, hospital stays, and response to immunotherapy are identified as independent risk factors for unsatisfactory prognosis in severe AE patients.

References

Han B, Dai Y, Peng J, Yuan T, Yin Q, Yang L . Study on clinical features and factors related to long-term outcomes of antibody-negative autoimmune encephalitis. Ann Clin Transl Neurol. 2024; 11(5):1325-1337. PMC: 11093238. DOI: 10.1002/acn3.52049. View

Zhou H, Deng Q, Yang Z, Tai Z, Liu K, Ping Y . Performance of the clinical assessment scale for autoimmune encephalitis in a pediatric autoimmune encephalitis cohort. Front Immunol. 2022; 13:915352. PMC: 9613941. DOI: 10.3389/fimmu.2022.915352. View

Dalmau J, Geis C, Graus F . Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 2017; 97(2):839-887. PMC: 5539405. DOI: 10.1152/physrev.00010.2016. View

Macher S, Bsteh G, Hoftberger R, Berger T, Rommer P, Zrzavy T . Clinical scales in autoimmune encephalitis-A retrospective monocentric cohort study. Ann Clin Transl Neurol. 2023; 10(10):1768-1775. PMC: 10578879. DOI: 10.1002/acn3.51865. View

Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer M . A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology. 2018; 92(3):e244-e252. PMC: 6340387. DOI: 10.1212/WNL.0000000000006783. View

Abboud H, Probasco J, Irani S, Ances B, Benavides D, Bradshaw M . Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021; . PMC: 8292591. DOI: 10.1136/jnnp-2020-325302. View

Broadley J, Wesselingh R, Seneviratne U, Kyndt C, Beech P, Buzzard K . Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium. Front Immunol. 2021; 11:597858. PMC: 7840591. DOI: 10.3389/fimmu.2020.597858. View

Ricken G, Schwaiger C, De Simoni D, Pichler V, Lang J, Glatter S . Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. Front Neurol. 2018; 9:841. PMC: 6191500. DOI: 10.3389/fneur.2018.00841. View

Molina R, Conzatti L, da Silva A, Goi L, Costa B, Machado D . Detection of autoantibodies in central nervous system inflammatory disorders: Clinical application of cell-based assays. Mult Scler Relat Disord. 2019; 38:101858. DOI: 10.1016/j.msard.2019.101858. View

10.

Gable M, Sheriff H, Dalmau J, Tilley D, Glaser C . The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012; 54(7):899-904. PMC: 3297648. DOI: 10.1093/cid/cir1038. View

11.

Cai M, Lai Q, Zheng Y, Fang G, Qiao S, Shen C . Validation of the Clinical Assessment Scale for Autoimmune Encephalitis: A Multicenter Study. Neurol Ther. 2021; 10(2):985-1000. PMC: 8412851. DOI: 10.1007/s40120-021-00278-9. View

12.

Yu Y, Wu Y, Cao X, Li J, Liao X, Wei J . The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity. Mult Scler Relat Disord. 2020; 47:102604. DOI: 10.1016/j.msard.2020.102604. View

13.

Dubey D, Pittock S, Kelly C, McKeon A, Lopez-Chiriboga A, Lennon V . Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018; 83(1):166-177. PMC: 6011827. DOI: 10.1002/ana.25131. View

14.

Al-Ansari A, Robertson N . Autoimmune encephalitis: clinical presentation, investigation and treatment. J Neurol. 2021; 268(10):3935-3937. PMC: 8463356. DOI: 10.1007/s00415-021-10800-6. View

15.

Titulaer M, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T . Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013; 12(2):157-65. PMC: 3563251. DOI: 10.1016/S1474-4422(12)70310-1. View

16.

Cheng X, Li Y, Wang Y, Sun Y, Lian Y . Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis. J Neuroimmunol. 2023; 383:578203. DOI: 10.1016/j.jneuroim.2023.578203. View

17.

Schubert J, Bramer D, Huttner H, Gerner S, Fuhrer H, Melzer N . Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm. 2018; 6(1):e514. PMC: 6278855. DOI: 10.1212/NXI.0000000000000514. View

18.

Lee W, Lee S, Moon J, Sunwoo J, Byun J, Lim J . Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics. 2016; 13(4):824-832. PMC: 5081109. DOI: 10.1007/s13311-016-0442-6. View

19.

Hansen N, Timaus C . Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge. J Neural Transm (Vienna). 2020; 128(1):1-14. PMC: 7815593. DOI: 10.1007/s00702-020-02258-z. View

20.

Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y . Clinical Characteristics and Prognosis of Severe Anti-N-methyl-D-aspartate Receptor Encephalitis Patients. Neurocrit Care. 2018; 29(2):264-272. DOI: 10.1007/s12028-018-0536-6. View